在乳腺癌的辅助药物abemaciclib治疗期间,报告了一种渐进的多焦点白脑病变
Ricard Borras-Ferreres1, Dimitri Peterlana2, Francesca Segatta2
1Internal Medicine, San Lorenzo Hospital, APSS, Trento, Italy. ricard.borrasferreres@apss.tn.it.
Journal of neurovirology
|December 24, 2025
概括
像abemaciclib这样的循环素依赖性激酶 (CDK) 4/6抑制剂治疗乳腺癌. 一个案例研究显示,在abemaciclib治疗期间发生的渐进性多焦点白细胞脑病变 (PML),表明了超越传统免疫抑制的潜在联系.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 病毒学 病毒学
背景情况:
- 循环素依赖激酶 (CDK) 4和6抑制剂是发光乳腺癌的标准治疗方法.
- 渐进性多焦点白细胞大脑病变 (PML) 通常与严重的免疫抑制有关.
- 阿贝马西克利布是一种CDK 4/6抑制剂,用于辅助性和转移性乳腺癌的治疗.
研究的目的:
- 报告一个罕见的PML病例,发生在乳腺癌辅助abemaciclib治疗期间.
- 研究可能的机制,将abemaciclib与PML发展联系在一起,特别是在没有明显的免疫抑制的情况下.
主要方法:
- 一个70岁的妇女患有局部发达的导管性乳腺癌的病例报告.
- 对神经功能障碍和脑成像 (MRI) 的临床监测.
- 在血液和脑脊液 (CSF) 中检测了约翰·坎宁汉多瘤病毒 (JCPyV) 基因组.
主要成果:
- 患者在经过18个月的abemaciclib.lib治疗后出现了神经症状和脑损伤.
- 排除了转移性疾病的可能性.
- 在血液和CSF中检测到JCPyVDNA,证实了PML.
- 没有发现显著的免疫细胞计数变化或同时接受免疫抑制治疗.
结论:
- 阿贝马西克利布治疗可能与PML风险增加有关,可能是通过经典免疫抑制以外的机制.
- 阿贝马西利布的高脑透率可能有助于JCPyV的重新激活.
- 需要进一步的研究来阐明由abemaciclib引起的特定免疫变化,这些变化可能会使患者易患PML.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:22Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:14Antiepileptic Drugs: Glutamate Antagonists
851
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
851